Side-by-side · Research reference
CortagenvsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/35 cited
BPhase 3HUMAN-REVIEWED25/54 cited
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
Injectable · Animal models
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
Cortagen
Survodutide
Primary target
Cerebral cortex tissue — molecular targets under investigation
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
—
—
Origin
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
—
Antibody development
—
—
02Dosage Protocols
Parameter
Cortagen
Survodutide
Animal model dose (rat)
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
—
Avian model dose (chicken)
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
—
Human peripheral nerve study
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.
—
Evidence basis
Animal mechanistic studies
Phase 2 RCT (obesity) · Phase 3 ongoing
Frequency
—
Once weekly
03Metabolic / Fat Loss Evidence
Parameter
Cortagen
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
Cortagen
Survodutide
Antioxidant suppression
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
—
Immune/hemostasis effects
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
—
Human safety data
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
Cortagen
—Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
Cortagen
—Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
Cortagen
Survodutide
1. Preparation
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Injection site
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
—
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.